June 19, 2019 Louis Arcudi III Hopedale, MA 01747 Re: Amended and Restated Employment Terms Dear Lou:Millendo Therapeutics, Inc. • August 12th, 2019 • Pharmaceutical preparations
Millendo Therapeutics US, Inc. (the “Company”) desires to amend and restate the terms of your employment as the Chief Financial Officer of the Company pursuant to the terms of this letter (the “Agreement”). Subject to your execution of this Agreement, effective as of January 1, 2019 (the “Effective Date”) this Agreement amends, restates and supersedes in its entirety your Employment Terms with Millendo Therapeutics US, Inc. (formerly known as Millendo Therapeutics, Inc.) dated November 1, 2018 (the “Prior Agreement”).
June 7, 2019 Julia C. Owens Ann Arbor, MI 48103 Re: Amended and Restated Employment Terms Dear Julia:Millendo Therapeutics, Inc. • August 12th, 2019 • Pharmaceutical preparations
Millendo Therapeutics US, Inc. (the “Company”) desires to amend and restate the terms of your employment as the President and Chief Executive Officer of the Company pursuant to the terms of this letter (the “Agreement”). Subject to your execution of this Agreement, effective as of January 1, 2019 (the “Effective Date”) this Agreement amends, restates and supersedes in its entirety your employment terms with Millendo Therapeutics US, Inc. (formerly known as Atterocor, Inc.) dated July 25, 2012 (the “Prior Agreement”).
License AgreementLicense Agreement • August 12th, 2019 • Millendo Therapeutics, Inc. • Pharmaceutical preparations
with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (“Roche US”; Roche Basel and Roche US together referred to as “Roche”)
